Professor, Leukemia; Executive Director-Cancer Medicine for MDACC Cancer Network | Director #BPDCN Program | Co-Section Head, MPN #MPNSM ;Tweets:my own opinions
Thrilled to see our paper โ the largest study ever of pediatric Castleman disease โ published and able to be used by clinicians to treat their pediatric patients! https://t.co/SHlXRJWVf2 please help to share this post so doctors are aware of this study and patients can benefit!
Outcome heterogeneity in CALR-mutated MPNs โ a detailed institutional cohort with over 2 decades of follow-up, delineating high-risk factors specifically in CALR-driven MPN. Esp as mutCALR directed Rx accelerate @reshamawalkar @HopkinsMedicine https://t.co/f4hblGdOCM
Grateful to our patients and colleagues for all we have learned from them while working on our review of the immune checkpoint inhibitor journey. We keep learning to take better care of our patients and improve treatment outcomes.
https://t.co/waBC3oQE7i
๐๐๐Thank you ๐ @VJHemOnc & and to our MPN & MDS communities for the invitation- I was honored to deliver a Keynote talk this year at the iwMDS /iwMPN meeting on #BPDCN Exciting Progress & Major Updates for 2026 & Beyond | @AmiBPatelMD@TheElfLab@mpdrc@harrisoncn1
Thrilled to spread the word about the next @AACR Targeting RAS Special Conference!
Looking forward to bringing the RAS community together again for new mechanisms, therapies & clinical advances.
Bring us your best RAS scienceโthe new, exciting & unexpected #AACRras27